SNY Sanofi
Company Analysis
Latest News
Sanofi seeks FDA approval, Nexviazyme hits goals in rare infant disease
Sanofi announced on June 30, 2026, that Nexviazyme met all primary and secondary goals in its Phase 3 Baby-COMET study. The trial evaluated the drug in...
Sanofi faces EU antitrust probe, allegedly disparaging rival Fluad vaccine
The European Commission launched a formal antitrust investigation into Sanofi for alleged anticompetitive practices. Regulators are probing whether the French...
Sanofi Secures Japan Approval for Wayrilz to Treat Rare Blood Disorder
Japan's Ministry of Health, Labour and Welfare approved Sanofi's Wayrilz (rilzabrutinib) for chronic immune thrombocytopenia (ITP). This rare autoimmune...
Sanofi secures EU approval for Cenrifki, first treatment for non-relapsing SPMS
The European Commission approved Sanofi’s drug Cenrifki (tolebrutinib) for adults with secondary progressive multiple sclerosis (SPMS) without recent relapses....
Sanofi Appoints Roche Veteran Paulo Fontoura as New Global Head of R&D
Sanofi has named Paulo Fontoura as its new Executive Vice President and Global Head of Pharma Research & Development, effective September 1, 2026. The...
Sanofi Reports Long-Term Riliprubart Gains in CIDP, Countering Phase 3 Setback
Sanofi reported new Phase 2 trial findings for riliprubart at the 2026 Peripheral Nerve Society Annual Meeting. Long-term treatment over 76 weeks led to...
Sanofi’s Tzield wins FDA approval for youth, slowing diabetes progression
The FDA granted accelerated approval for Sanofi’s Tzield (teplizumab-mzwv) for patients aged 8 to 17. This indication targets children and adolescents recently...
Sanofi Q1 2026 Earnings Preview: What Analysts Expect on April 23, 2026
Sanofi is expected to report Q1 2026 revenue of $11.99 billion and EPS of $1.04, with the stock currently trading near $48.06 compared to an average analyst...